Newswise — May 10, 2023 – Robotic-arm assisted unicompartmental knee arthroplasty (UKA) provides good long-term outcomes, with implant survival and patient satisfaction rates exceeding 90% at 10 years' follow-up, reports a study in TheJournal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
"This prospective multicenter study found high 10-year survivorship and patient satisfaction following robotic-arm-assisted medial UKA," concludes the report, led by Tarik Bayoumi, MD, of the Hospital for Special Surgery, Weill Medical College of Cornell University, New York.
First data on long-term outcomes of robot-assisted UKA
In UKA, just one of three compartments of the knee – the medial compartment – is replaced with a prosthesis. Because it preserves most of the normal knee anatomy, UKA may offer a shorter hospital stay and greater knee range of motion postoperatively, compared with the more common and extensive total knee arthroplasty (TKA).
Previous studies have shown that the use of a surgeon-controlled robotic arm can improve the precision of UKA, potentially avoiding technical errors that can affect outcomes postoperatively. Previous studies have reported high survivorship free from conversion to TKA at mid-term follow-up following robotic-arm assisted UKA. "Given the increased use of robotic systems in knee arthroplasty and the favorable early outcomes, the current challenge lies in demonstrating whether these results can be maintained at longer-term follow-up," the researchers write.
In their prospective study, Dr. Bayoumi and colleagues analyzed the 10-year outcomes of 411 knees in 366 patients undergoing robotic-arm assisted medial UKA at four participating centers. Fifty-seven percent of patients were male, and the average age at surgery was 67.2 years.
All procedures were performed by four experienced knee arthroplasty surgeons who received special training and practice in robotic-arm-assisted UKA. The study included 10-year follow-up data on the initial series of patients who received a specific type of cemented implant (Restoris MCK System) and a third-generation robotic-guided surgical system (Mako Robotic-Arm Assisted System).
Ten years later, high satisfaction rates and freedom from TKA
Follow-up results showed good outcomes of robotic-assisted UKA. Overall survivorship with the medial UKA implant still in place was 91.7%. Of the 29 revisions, 26 were a conversion to TKA, for a survivorship of 92.6%.
The rate of conversion to TKA was about twice as high in women compared to men: hazard ratio of 2.3. Revision risk was also higher for patients with a body mass index of 30 kg/m2 or higher; and for younger patients, likely reflecting a more active lifestyle and increased demands on the knee. Most revision surgeries resulted from unexplained knee pain or aseptic loosening.
Patient satisfaction ratings supported the good outcomes of robotic-assisted UKA. "Of all patients without revision, 91% reported being either very satisfied or satisfied with their operative knee, while 4% were dissatisfied or very dissatisfied," the researchers write.
The high rates of survivorship and patient satisfaction are consistent with long-term studies of conventional UKA. The researchers note some limitations of their study, highlighting the need for prospective comparative studies. Dr. Bayoumi comments, "Since this was a single-arm trial, it remains to be determined whether robotic-arm assistance for UKA results in improved outcomes compared to conventional UKA."
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.